Beta-1,6-N-acetylglucosamine-branched N-glycan (β1,6-GlcNAc branched N-glycan) (β1,6-GlcNAc branched N-glycan)

Beta-1,6-N-acetylglucosamine (β1,6GlcNAc)-branched N-glycans are complex carbohydrate structures synthesized on cell surface proteins by the enzyme mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetylglucosaminyltransferase (MGAT5). These glycans are frequently overexpressed in various cancers and are strongly associated with tumor progression, epithelial-mesenchymal transition (EMT), and metastasis [1][3]. Mechanistically, the β1,6-branching increases the affinity of cell surface receptors, such as EGFR and TGF-β receptor, for galectins, forming a galectin-glycan lattice that inhibits receptor endocytosis and sustains oncogenic signaling [2]. Additionally, these branched glycans contribute to immune evasion by impairing T-cell activation and promoting an immunosuppressive microenvironment [4]. Therapeutic approaches include small-molecule inhibitors of the biosynthetic pathway, such as Swainsonine, and the development of lectin-based or antibody-based agents that specifically recognize these glyco-epitopes on malignant cells [3]. Targeting these glycans provides a strategy to simultaneously disrupt multiple growth factor pathways and enhance anti-tumor immunity.

Other names

GnT-V productsL-PHA-reactive glycansBeta-1,6-branched oligosaccharidesMGAT5-modified N-glycansComplex N-glycans

Inhibition of N-glycan branching via biosynthetic enzyme blockade or disruption of the galectin-glycan lattice